Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Evidence-Based Management of Anticoagulant Therapy
LHD Logo Venous Thromboembolism Reducing the Risk DATE.
Treatment of Acute Pulmonary Embolism
2012 CHEST Guideline Update VTE prophylaxis, DVT treatment, and Atrial Fibrillation LT Tabatha Welker, PharmD Pharmacy Resident, PHS Claremore Indian Hospital.
IN THE NAME OF GOD. Prevention of Venous Thromboembolism Dr.Shirali.
Deep Vein Thrombosis and Pulmonary Embolism prophylaxis in Asian general surgical patients: is it necessary?  AMY KOK Caritas Medical Centre.
VTE in abdominal-pelvic surgery patients
Antithrombotic Therapy for Venous Thromboembolic Diseases
DVT PROPHYLAXIS SUNDIP PATEL 7 / 15 / BACKGROUND Deep Vein Thrombosis is a common, yet preventable peri-operative complication Highest risk in critical.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Venous Thromboembolism Prophylaxis and Management in the Medical Patient at Sisters of Charity Hospital Jeffrey Parker, DO Dr. Nashat Rabadi, MD Sisters.
Prophylaxis of Venous Thromboembolism
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Deep Vein Thrombosis (DVT)
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Beverley Hunt Simon Noble Hospital Acquired Venous Thromboembolism.
RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.
VTE Prophylaxis Alert to providers and nursing Go live June 24, 2014.
 When untreated, general postsurgical patients risk for Deep Venous Thrombosis (DVT) is 19%-25% (Buckner, et al., 2013).  Post surgical orthopedic patients.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DVT/VTE Nursing Protocol (Deep Vein Thrombosis) (Venous Thromboembolism) Presented by Maribeth Desiongco MA, RN-BC 2008.
Preventing Venous Thromboembolism in Surgical and Medical Patients Susan Kahn MD MSc Director, JGH Thrombosis Program March 2011.
Medical Patients – VTE Prevention Dale W. Bratzler, DO, MPH Professor and Associate Dean, College of Public Health Professor of Medicine, College of Medicine.
DVT Prophylaxis in Orthopedic Patients Rogers Kyle 11/27/12.
Pain Agitation & Delirium SCCM Pain assessment i. We recommend that pain be routinely monitored in all adult ICU patients (+1B). ii. The Behavioral.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
1 VTE Protocol Presented by: Selina Baskins, RN Quality Coordinator.
Risk assessment for VTE
Peter Davies Senior Pharmacist.  Venous thromboembolic prevention is a DH patient safety priority  NICE clinical guideline venous thromboembolism reducing.
Preoperative Management of Hypoxic Patients
Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
LIFEBLOOD THE Thrombosis CHARITY LIFEBLOOD THE Thrombosis CHARITY NICE Clinical Guideline 46.
VTE Prevention In Action Interactive Case Scenarios.
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
Cost-Consciousness Assignment Ollie Ross DSR 2. Adherence to ACP DVT prophylaxis guidelines Objective: Evaluate adherence to ACP DVT prophylaxis guidelines.
Risk Assessment for VTE. Which of the following best describes you?
Prophylaxis Diagnosis Treatment Venous Thromboembolism Management.
Mandatory Training: VTE prevention and anticoagulation practice Mandatory Training: VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis.
Quality and Patient Safety Council May 27, 2014 Presented By Susan M. Blackhurst BS, RN & Eric Jean BSN, RN, CCRN.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Venous Thromboembolism (VTE) Prophylaxis at Cesarean Section Phillip N. Rauk, MD.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Prevention of Venous Thromboembolism in Nonsurgical Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.
1 MMM October 2008 AVAIL ME Project Audit of Venous Thromboembolism Management in Middle East Hospitals Elham Mir,MD MPH Medical Affairs Clinical Operation.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Prevention of Venous Thromboembolism in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Spotlight Case January 2006 An Ounce of Prevention.
Outpatient DVT assessment & treatment Daniel Gilada.
VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.
Venous Thromboembolism Prophylaxis for Medical Inpatients
Evidence-Based Management of Anticoagulant Therapy
Venous Thromboembolism Prophylaxis (VTE)
Antithrombotic Therapy in Atrial Fibrillation
Antithrombotic Therapy in Peripheral Artery Disease
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
Thrombosis, Cancer, and NOACs
Fibrillazione atriale
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Venous Thromboembolism Prophylaxis in Hospitalized Patients
Presentation transcript:

Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008

Do you have a Thromboprophylaxis Policy ?

Hospital Thromboprophylaxis Policy For every general hospital, we recommend that a formal, active strategy that addresses the prevention of VTE be developed (Grade 1A) We recommend that the local thromboprophylaxis strategy be in the form of a written, institution-wide thromboprophylaxis policy (Grade 1C) We recommend the use of strategies shown to increase thromboprophylaxis adherence, – including the use of computer decision support systems (Grade 1A), – preprinted orders (Grade 1B), – and periodic audit and feedback (Grade 1C). Passive methods such as distribution of educational materials or educational meetings are not recommended as sole strategies to increase adherence to thromboprophylaxis (Grade 1B).

Do you risk assess your patients in your ICU for VTE & Bleeding ?

Critical Care 8.1. For patients admitted to a critical care unit, we recommend routine assessment for VTE risk and routine thromboprophylaxis in most (Grade 1A).

Risk Assessment ICUHigh Risk HeparinsMDNoneReason A1310none3ICH, GpIIbIIa, B73GCS-14ICH, CKD, Postop-2 C121IPC-47ICH/SDH-4, GI bleed 3 D185GCS-3(+3)10Postop-3, Sepsis-4, CCF-1, Trauma-1, MI-1

8.2. For critical care patients who are at moderate risk for VTE (eg, medically ill or postoperative general surgery patients), we recommend using LMWH or LDUH thromboprophylaxis (Grade 1A).

General Surgery For moderate-risk general surgery patients who are undergoing a major procedure for benign disease, we recommend thromboprophylaxis with LMWH, LDUH, or fondaparinux (Grade 1A) For higher-risk general surgery patients who are undergoing a major procedure for cancer, we recommend thromboprophylaxis with LMWH, LDUH three times daily, or fondaparinux (each Grade 1A).

Critical Care 8.3. For critical care patients who are at higher risk (eg, following major trauma or orthopedic surgery), we recommend LMWH thromboprophylaxis (Grade 1A) For critical care patients who are at high risk for bleeding, we recommend the optimal use of mechanical thromboprophylaxis with GCS and/or IPC at least until the bleeding risk decreases (Grade 1A). When the high bleeding risk decreases, we recommend that pharmacologic thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis (Grade 1C).

Medical Conditions For acutely ill medical patients admitted to hospital with congestive heart failure or severe respiratory disease, or who are confined to bed and have one or more additional risk factors, including active cancer, previous VTE, sepsis, acute neurologic disease, or inflammatory bowel disease, we recommend thromboprophylaxis with LMWH (Grade 1A), LDUH (Grade 1A), or fondaparinux (Grade 1A) For medical patients with risk factors for VTE, and for whom there is a contraindication to anticoagulant thromboprophylaxis, we recommend the optimal use of mechanical thromboprophylaxis with GCS or IPC (Grade 1A).

Trauma For major trauma patients, if LMWH thromboprophylaxis is contraindicated due to active bleeding or high risk for clinically important bleeding, we recommend that mechanical thromboprophylaxis with IPC or possibly with GCS alone be used (Grade 1B). When the high bleeding risk decreases, we recommend that pharmacologic thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis (Grade 1C).

Neurosurgery For patients undergoing major neurosurgery, we recommend that thromboprophylaxis be used routinely (Grade 1A), with optimal use of IPC (Grade 1A). Acceptable alternatives to IPC are post operative LMWH (Grade 2A) or LDUH (Grade 2B) For patients undergoing major neurosurgery who have a particularly high thrombosis risk, we suggest that a mechanical method (ie, GCS and/or IPC) be combined with a pharmacologic method (ie, postoperative LMWH or LDUH) (Grade 2B).

Acute Spinal Cord Injury For patients with acute SCI, we recommend thromboprophylaxis with LMWH, commenced once primary hemostasis is evident (Grade 1B). Alternatives include the combined use of IPC and either LDUH (Grade 1B) or LWMH (Grade 1C).

Mechanical Methods of Thromboprophylaxis We recommend that mechanical methods of thromboprophylaxis be used primarily in patients at high risk of bleeding (Grade 1A), or possibly as an adjunct to anticoagulant-based thromboprophylaxis (Grade 2A) For patients receiving mechanical methods of thromboprophylaxis, we recommend that careful attention be directed toward ensuring the proper use of, and optimal adherence with, these methods (Grade 1A).

Problems with Mechanical Devices Less effective than pharmacological measures Pressure Sores & Non Optimal Use GCS reduced risk from 27% to 13% GCS + UFH from 15%-2% GCS contraindicated in arterial insufficiency GCS not effective in Strokes (Lancet 2010) IPC reduced DVT risk from 7%-2% IPC contraindicated in DVT for risk of PE Should not restrict ambulation

Renal Impairment and Anticoagulant Dosing We recommend that renal function be considered when making decisions about the use and/or the dose of LMWH, fondaparinux, and other antithrombotic drugs that are cleared by the kidneys, particularly in elderly patients, patients with diabetes mellitus, and those at high risk for bleeding(Grade 1A) Depending on the circumstances, we recommend one of the following options in this situation: avoiding the use of an anticoagulant that bioaccumulates in the presence of renal impairment, using a lower dose of the agent, or monitoring the drug level or its anticoagulant effect (Grade 1B).

Barriers Overestimation of Risk of Bleeding than Clotting Poor Awareness

Future The newer oral anticoagulants – rivaroxaban (Johnson & Johnson/Bayer) – dabigatran (Boehringer Ingelheim)

Summary All ICUs should develop a VTE prophylaxis policy All patients should be assessed for risk of VTE daily Raise awareness of VTE Surgeons have to be convinced about VTE prevention